These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 16489001)

  • 21. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain.
    Esteban Cardeñosa E; Bolufer Gilabert P; Palanca Suela S; Oltra Soler S; Barragán González E; Velasco Sampedro E; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E;
    Breast Cancer Res Treat; 2008 Nov; 112(1):69-73. PubMed ID: 18060494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting.
    van der Hout AH; van den Ouweland AM; van der Luijt RB; Gille HJ; Bodmer D; Brüggenwirth H; Mulder IM; van der Vlies P; Elfferich P; Huisman MT; ten Berge AM; Kromosoeto J; Jansen RP; van Zon PH; Vriesman T; Arts N; Lange MB; Oosterwijk JC; Meijers-Heijboer H; Ausems MG; Hoogerbrugge N; Verhoef S; Halley DJ; Vos YJ; Hogervorst F; Ligtenberg M; Hofstra RM
    Hum Mutat; 2006 Jul; 27(7):654-66. PubMed ID: 16683254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pitfalls and caveats in BRCA sequencing.
    Bellosillo B; Tusquets I
    Ultrastruct Pathol; 2006; 30(3):229-35. PubMed ID: 16825125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma.
    Majdak EJ; Debniak J; Milczek T; Cornelisse CJ; Devilee P; Emerich J; Jassem J; De Bock GH
    Cancer; 2005 Sep; 104(5):1004-12. PubMed ID: 16047333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs.
    Vreeswijk MP; Kraan JN; van der Klift HM; Vink GR; Cornelisse CJ; Wijnen JT; Bakker E; van Asperen CJ; Devilee P
    Hum Mutat; 2009 Jan; 30(1):107-14. PubMed ID: 18693280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants.
    Lovelock PK; Healey S; Au W; Sum EY; Tesoriero A; Wong EM; Hinson S; Brinkworth R; Bekessy A; Diez O; Izatt L; Solomon E; Jenkins M; Renard H; Hopper J; Waring P; Tavtigian SV; Goldgar D; Lindeman GJ; Visvader JE; Couch FJ; Henderson BR; Southey M; Chenevix-Trench G; Spurdle AB; Brown MA;
    J Med Genet; 2006 Jan; 43(1):74-83. PubMed ID: 15923272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of BRCA1 and BRCA2 mutation status using post-irradiation assays of lymphoblastoid cell lines is compromised by inter-cell-line phenotypic variability.
    Lovelock PK; Wong EM; Sprung CN; Marsh A; Hobson K; French JD; Southey M; Sculley T; Pandeya N; Brown MA; Chenevix-Trench G; Spurdle AB; McKay MJ;
    Breast Cancer Res Treat; 2007 Sep; 104(3):257-66. PubMed ID: 17063265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.
    Willems AJ; Dawson SJ; Samaratunga H; De Luca A; Antill YC; Hopper JL; Thorne HJ;
    Clin Cancer Res; 2008 May; 14(10):2953-61. PubMed ID: 18445692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables.
    Johannsdottir HK; Johannesdottir G; Agnarsson BA; Eerola H; Arason A; Johannsson OT; Heikkilä P; Egilsson V; Olsson H; Borg A; Nevanlinna H; Barkardottir RB
    Anticancer Res; 2004; 24(5A):2681-7. PubMed ID: 15521105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.
    Vogel KJ; Atchley DP; Erlichman J; Broglio KR; Ready KJ; Valero V; Amos CI; Hortobagyi GN; Lu KH; Arun B
    J Clin Oncol; 2007 Oct; 25(29):4635-41. PubMed ID: 17925560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo.
    Quaresima B; Faniello MC; Baudi F; Crugliano T; Di Sanzo M; Cuda G; Costanzo F; Venuta S
    Oncol Rep; 2006 Oct; 16(4):811-5. PubMed ID: 16969499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCA1 and BRCA2 mutations in a South American population.
    Jara L; Ampuero S; Santibáñez E; Seccia L; Rodríguez J; Bustamante M; Martínez V; Catenaccio A; Lay-Son G; Blanco R; Reyes JM
    Cancer Genet Cytogenet; 2006 Apr; 166(1):36-45. PubMed ID: 16616110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of heterozygosity analysis in ductal lavage samples from BRCA1 and BRCA2 carriers: a cautionary tale.
    Antill YC; Mitchell G; Johnson SA; Devereux L; Milner A; Phillips KA; Campbell IG
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1396-8. PubMed ID: 16835342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.
    Li WF; Hu Z; Rao NY; Song CG; Zhang B; Cao MZ; Su FX; Wang YS; He PQ; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Liu XY; Zhou J; Wang L; Zhao L; Liu YB; Yuan WT; Yang L; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2008 Jul; 110(1):99-109. PubMed ID: 17851763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus.
    Loizidou M; Marcou Y; Anastasiadou V; Newbold R; Hadjisavvas A; Kyriacou K
    Clin Genet; 2007 Feb; 71(2):165-70. PubMed ID: 17250666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advantages of the high resolution melting in the detection of BRCA1 or BRCA2 mutation carriers.
    Jiménez Ide J; Esteban Cardeñosa E; Palanca Suela S; González EB; Bolufer Gilabert P;
    Clin Biochem; 2009 Oct; 42(15):1572-6. PubMed ID: 19616529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
    J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.